Elodyst 50 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 05 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients (u2265 65 years) with newly diagnosed acute myeloid leukaemia (AML).
Dosage (summary)
20 mg/mu00b2 IV infusion over 1 hour daily for 5 days, repeated every 4 weeks.
Onset of Action / Duration
Onset: 4.3 months for response.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic in animal studies.
Key Drug Interactions
- Caution with other medicines activated by phosphorylation or metabolized by cytidine deaminase.
Contraindications
- Hypersensitivity to decitabine
- Lactating women
Common side effects
- Myelosuppression
- Infections
- Nausea
- Vomiting
- Diarrhoea
Counselling Points
- Use effective contraception during treatment
- Monitor for signs of infection
- Avoid driving if experiencing fatigue or anaemia.
Serious warnings
- Myelosuppression and complications likely
- Potential for interstitial lung disease
Important Disclaimer
The Elodyst 50 mg Powder for concentrate for solution for infusion professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
